Phase 1/2 Nivolumab + Plinabulin in NSCLC

Phase 1/2 Nivolumab + Plinabulin in NSCLC

Efficacy Synergy of Plinabulin with PD-1, CTLA-4

Efficacy Synergy of Plinabulin with PD-1, CTLA-4

* Data presented at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

The Phase 1/2 trial of Plinabulin with Nivolumab in patients with non-small lung cancer will evaluate the combination.

Animal studies provide indications of an immune MOA, which primarily acts through activation and proliferation of tumor antigen-specific CD4 T-cells, a white blood cell active in immune responses.

Study Status

Ongoing.

Study Design

Study BPI-2358-201, in collaboration with UCSD: with Nivolumab (240 mg) and Plinabulin (20 and 30 mg/m2) administered on days 1 and 14 of each 28 day cycle.

Study BPI-2358-202, in collaboration with Fred Hutchinson Cancer Research Center: with Nivolumab (3 mg/kg on day 1 and 14) and Plinabulin (13.5, 20, 30 or 40 mg/m2) on day 1, 8 and 15) administered in 28 day cycles.

Patient Population

Patients with 2nd/3rd line NSCLC

More Information

S. Yeh et al., A Phase 1 Trial Combining Plinabulin and Nivolumab for Metastatic Squamous NSCLC.,International Association for the Study of Lung Cancer, Abstract 602 /, P2.01-087, 2015.

Results of this trial were published as follows:

Nivolumab in Combination with Plinabulin in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)

Nivolumab and Plinabulin in Treating Patients with Stage IIIB-IV, Recurrent, or Metastatic Non-Small Cell Lung Cancer